Cyproheptadine Treatment of COVID-19-Induced Enteritis: Implications for Hyperinflammatory Phase Management-Reference-Cited by-同舟云学术

Cyproheptadine Treatment of COVID-19-Induced Enteritis: Implications for Hyperinflammatory Phase Management

Published:2023-04 Issue:4 Volume:10 Page:e01034
ISSN:2326-3253
Container-title:ACG Case Reports Journal
language:en
Short-container-title:ACG Case Rep J

Author:

Weinstock Leonard B.¹^ORCID,Reiersen Angela M.²,Jain Anshu³,Konstantinoff Katerina⁴,James William⁴,Jalali Farid⁵

Affiliation:

1. Specialists in Gastroenterology, Private Practice, St. Louis, MO

2. Washington University in St. Louis School of Medicine, St. Louis, MO

3. Department of Medicine, Missouri Baptist Medical Center, Creve Coeur, MO

4. Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO

5. Private Practice, Saddleback, CA

Abstract

ABSTRACT A patient presented with COVID-19-induced enteritis and colitis associated with a high D-dimer. Serotonin released by activated platelets can lead to inflammation and multiorgan failure in COVID-19 infection. Cyproheptadine blocks serotonin receptors. In light of a prior report that showed that cyproheptadine successfully treated neurologic sequelae in COVID-19, we applied this treatment to this patient. Rapid clinical improvement and reduction of D-dimer occurred after 3 doses of cyproheptadine. This inexpensive, well-tolerated, oral medication may be applicable to treat hyperinflammatory sequelae of COVID-19 infection.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference19 articles.

1. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms;Jin;Gut,2020

2. COVID-19, coronavirus, SARS-CoV-2 and the small bowel;Mönkemüller;Rev Esp Enferm Dig,2020

3. Enteritis and severe abdominal pain as the first presentation of Covid-19;Kecler-Pietrzyk;Ir Med J,2020

4. Intestinal ischemia in the COVID-19 era;Norsa;Dig Liver Dis,2020

5. Dual-histamine receptor blockade with cetirizine: Famotidine reduces pulmonary symptoms in COVID-19 patients;Hogan;Pulm Pharm Ther,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19-vaccine;Reactions Weekly;2024-04-27

2. Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial;eClinicalMedicine;2024-04